Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07325617

Tracking AI/LLM Literacy and Knowledge in Urology Outpatients (TALK-U)

This study is a one-time, questionnaire-based survey of adults attending a urology outpatient clinic. The investigators will examine whether patients who use AI chat tools based on large language models (LLMs), such as ChatGPT, before seeking care differ from non-users in (1) anxiety, (2) satisfaction with the clinic visit, and (3) awareness/understanding of their health condition.

Participants who provide written informed consent will complete a brief survey during their clinic visit (about 5-7 minutes). The survey includes a standardized anxiety scale (GAD-7), visual analog scales (0-10) for anxiety before and after the visit, satisfaction, and disease awareness, as well as questions about AI/LLM knowledge and use. Treating clinicians will not have access to participants' survey responses, and participation will not affect clinical care.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Dr.Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital

Ankara, Yenimahalle/Ankara, 06200, Turkey (Türkiye)

Location contact

Tuncel Uzel, MD

CONTACT

[email protected]

+90 312 336 09 09 ext. 5622

About this study

The TALK-U study is a cross-sectional, observational survey conducted in the urology outpatient clinic of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. The primary exposure is self-reported AI/LLM knowledge and use for health information (e.g., whether participants have used ChatGPT or similar tools, frequency, awareness of AI, and purpose of use). The primary outcome is anxiety measured by GAD-7 at the time of the clinic encounter. Secondary outcomes include (i) anxiety assessed on a 0-10 visual analog scale before and after the visit, (ii) outpatient visit satisfaction (0-10 VAS), and (iii) perceived disease awareness/understanding (0-10 VAS).

Eligible adult first-time urology outpatients who can complete the survey independently and provide informed consent will be invited during a 2-month recruitment period. Analyses will compare outcomes between AI/LLM users and non-users and explore associations with age group (<40, 40-60, >60), education level, and urology subspecialty category. Data will be analyzed using appropriate parametric/nonparametric tests depending on distribution, with p < 0.05 considered statistically significant.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older
  • First-time visit to the Urology Outpatient Clinic
  • Able to read and write and complete the questionnaire independently
  • Able to provide written informed consent

Exclusion criteria

  • Age under 18 years
  • Insufficient literacy to understand and complete the questionnaire
  • Severe hearing or visual impairment, or a neurological/psychiatric condition that prevents understanding and completing the survey
  • Refusal or inability to provide informed consent
  • Currently under follow-up for a known urologic condition (i.e., not a first-time urology outpatient visit)

Treatment and study plan

Primary outcomes

  1. Pre-visit Anxiety (VAS 0-10)

    Time frame: Day 0 (immediately before the outpatient visit)

    Self-rated anxiety on a 0-10 visual analog scale (VAS), where 0 indicates no anxiety and 10 indicates the highest possible anxiety. This measure reflects visit-related state anxiety prior to clinician encounter.

Secondary outcomes

  1. Post-visit Anxiety (VAS 0-10)

    Time frame: Day 0 (immediately after the outpatient visit)

    Self-rated anxiety on a 0-10 VAS (0 = none, 10 = highest).

  2. Visit Satisfaction (VAS 0-10)

    Time frame: Day 0 (immediately after the outpatient visit)

    Self-rated satisfaction with the outpatient visit on a 0-10 VAS (0 = not satisfied at all, 10 = maximum satisfaction).

  3. Disease Awareness/Understanding (VAS 0-10)

    Time frame: Day 0 (during the outpatient clinic visit)

    Self-rated awareness/understanding of one's condition on a 0-10 VAS (0 = none, 10 = complete).

Other outcomes

  1. Baseline General Anxiety Symptoms (GAD-7 Total Score)

    Time frame: Day 0 (at enrollment; prior to or during the clinic visit)

    Total score on the 7-item GAD-7 questionnaire (range 0-21; higher scores indicate greater generalized anxiety symptoms). This measure will be used to account for baseline anxiety (trait-like symptoms) and to adjust analyses of VAS-based state anxiety out

Study contacts

Contact information is provided by the study sponsor or research team.

Mehmet Duvarcı, MD

CONTACT

[email protected]

+90 312 336 09 09 ext. 5616

Tuncel Uzel, MD

CONTACT

[email protected]

+90 312 336 09 09 ext. 5622

Sponsors and collaborators

Lead sponsor

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Other

Registry information

Official study title

The TALK-U Study: Tracking AI/LLM Knowledge and Use in Urology Outpatients and Its Association With Anxiety, Satisfaction, and Health Awareness-A Cross-Sectional Study

Acronym: TALK-U

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jan 8, 2026
Registry last updated
Jan 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.